{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T12:39:41Z","timestamp":1788698381897,"version":"build-2803163510"},"reference-count":37,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: This real-life study aimed to investigate the possible impact of D-VTd induction therapy on hematopoietic engraftment after autologous stem cell transplantation (auto-SCT). Methods: Sixty consecutive NDMM patients received four cycles of induction therapy with D-VTd. The conditioning regimen consisted of melphalan 200 mg\/m2. These patients were compared with a historical control group of 80 patients who received four cycles of VTd as induction therapy. Results: The median days to reach neutrophil and platelet engraftment significantly differed between patients treated with D-VTd (11 and 13 days, respectively) and VTd (10 and 12 days). Univariate Cox analyses show that patients treated with D-VTd had a hazard ratio of neutrophil engraftment that was 42% significantly lower than those in the VTd arm (HR: 0.58, p = 0.002), and a multivariate model confirmed this result. Patients treated with D-VTd developed FN more frequently. Univariate and multivariate logistic regressions revealed an association between D-VTd and FN. Delayed engraftment did not correlate with more extended hospitalization. No patients died in the first six months after transplantation. Conclusions: Our real-life study showed that a four-drug induction therapy containing DARA does not impact transplant safety outcomes.<\/jats:p>","DOI":"10.3390\/cancers16193307","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T09:16:10Z","timestamp":1727428570000},"page":"3307","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"first","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Gori","sequence":"additional","affiliation":[{"name":"Institute of Clinical Physiology (IFC-CNR), Section of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetana","family":"Porto","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Policastro","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-4141","authenticated-orcid":false,"given":"Martina","family":"Pitea","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Sgarlata","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1597-1913","authenticated-orcid":false,"given":"Ilaria Maria","family":"Delfino","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cogliandro","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Scopelliti","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Utano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pellicano","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Idato","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda Donatella","family":"Vincelli","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Marafioti","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Caterina","family":"Mic\u00f2","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lazzaro","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Loteta","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Alati","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande OspedaleMetropolitano\u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"},{"name":"Stem Cell Transplant Program CIC587, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Leanza","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, Grande Ospedale Metropolitano \u201cBianchi-Melacrino-Morelli\u201d, 89133 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"D\u2019Arrigo","sequence":"additional","affiliation":[{"name":"Institute of Clinical Physiology (IFC-CNR), Section of Reggio Calabria, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Luigi","family":"Tripepi","sequence":"additional","affiliation":[{"name":"Institute of Clinical Physiology (IFC-CNR), Section of Reggio Calabria, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7768-3925","authenticated-orcid":false,"given":"Annalisa","family":"Pitino","sequence":"additional","affiliation":[{"name":"Institute of Clinical Physiology (IFC-CNR), Section of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations between Health Access and Quality, Economic Resources, and Patient Empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: The (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.12998\/wjcc.v11.i29.7091","article-title":"Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma","volume":"11","author":"Wang","year":"2023","journal-title":"World J. Clin. Cases"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: Long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"174.e1","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Bigi, F., Manzato, E., Barbato, S., Talarico, M., Puppi, M., Masci, S., Sacchetti, I., Restuccia, R., Iezza, M., and Rizzello, I. (2024). Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients\u2014A Systematic Review. Pharmaceuticals, 17.","DOI":"10.3390\/ph17070944"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-140811","article-title":"Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use","volume":"136","author":"Luan","year":"2020","journal-title":"Blood"},{"key":"ref_11","first-page":"328","article-title":"Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients","volume":"22","author":"Zappaterra","year":"2024","journal-title":"Blood Transfus."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bigi, F., Tacchetti, P., Giorgi, A., Mazzocchetti, G., Solli, V., Barbato, S., Sinigaglia, B., Campanini, E., Favero, E., and Talarico, M. (2024). Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cells in Multiple Myeloma patients. Front. Haematol., 3.","DOI":"10.3389\/frhem.2024.1386973"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/bjh.19141","article-title":"Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti-CD38 therapy","volume":"204","author":"Venglar","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1080\/10428194.2023.2253479","article-title":"Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation","volume":"64","author":"Terpos","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2023-185907","article-title":"Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis","volume":"142","author":"Cavallaro","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1182\/blood-2023-188780","article-title":"Autologous STEM Cell Collection after Daratumumab, Bortezomib, Thalidomide and Dexamethasone versus Bortezomib, Thalidomide and Dexamethasone in NEWLY Diagnosed Multiple Myeloma: A Real-Life Monocentric Italian Experience","volume":"142","author":"Fazio","year":"2023","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-142115","article-title":"Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant","volume":"136","author":"Manjappa","year":"2020","journal-title":"Blood"},{"key":"ref_19","first-page":"E8","article-title":"Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma","volume":"95","author":"Sidiqi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kr\u00f6ger, N. (2019). Graft Failure. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet], Springer. [7th ed.]. Chapter 41.","DOI":"10.1007\/978-3-030-02278-5"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Carreras, E., Dufour, C., Mohty, M., and Kr\u00f6ger, N. (2019). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet], Springer. [7th ed.].","DOI":"10.1007\/978-3-030-02278-5"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41409-024-02248-9","article-title":"Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: A report from the EBMT","volume":"59","author":"Passweg","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JOP.19.00335","article-title":"Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies","volume":"16","author":"Parrondo","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mor\u00e8, S., Corvatta, L., Manieri, V.M., Saraceni, F., Scortechini, I., Mancini, G., Fiorentini, A., Olivieri, A., and Offidani, M. (2022). Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?. Cells, 11.","DOI":"10.3390\/cells11040606"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): Final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1182\/blood-2022-171098","article-title":"Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma","volume":"140","author":"Oza","year":"2022","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Sureda, A., Corbacioglu, S., Greco, R., Kr\u00f6ger, N., and Carreras, E. (2024). Vaccinations. The EBMT Handbook, Springer.","DOI":"10.1007\/978-3-031-44080-9"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3109\/10428194.2014.931952","article-title":"A home-care, early discharge model after autografting in multiple myeloma: Results of a three-arm prospective, non-randomized study","volume":"56","author":"Martino","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Martino, M., Paviglianiti, A., Memoli, M., Martinelli, G., and Cerchione, C. (2020). Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.592487"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.clml.2017.05.018","article-title":"Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model versus an Early Discharge Model","volume":"17","author":"Martino","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/19\/3307\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:05:10Z","timestamp":1760112310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/19\/3307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":37,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["cancers16193307"],"URL":"https:\/\/doi.org\/10.3390\/cancers16193307","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}